WO2024116156 - RECOMBINANT PROTEINS COMPRISING NON-LTR RETROTRANSPOSON-DERIVED POLYPEPTIDES FOR GENE DELIVERY AND INSERTION

National phase entry is expected:
Publication Number WO/2024/116156
Publication Date 06.06.2024
International Application No. PCT/IB2023/062154
International Filing Date 02.12.2023
Title [English] RECOMBINANT PROTEINS COMPRISING NON-LTR RETROTRANSPOSON-DERIVED POLYPEPTIDES FOR GENE DELIVERY AND INSERTION [French] PROTÉINES RECOMBINANTES COMPRENANT DES POLYPEPTIDES DÉRIVÉS DE RÉTROTRANSPOSONS NON-LTR POUR L'ADMINISTRATION ET L'INSERTION DE GÈNES
Applicants ** EXSILIO THERAPEUTICS LTD 2 Ilan Ramon 7403635 Ness Ziona, IL BEN SHUSHAN-GOLECZKI, Yaron c/o EXSILIO THERAPEUTICS LTD 2 Ilan Ramon 7403635 Ness Ziona, IL KOWALSMAN, Noga c/o EXSILIO THERAPEUTICS LTD 2 Ilan Ramon 7403635 Ness Ziona, IL
Inventors ** TRUDEAU, Devin c/o EXSILIO THERAPEUTICS LTD 2 Ilan Ramon 7403635 Ness Ziona, IL
Priority Data 63/429,955  02.12.2022  US
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 6059
EPO Filing, Examination 112335
Japan Filing 576
South Korea Filing 576
USA Filing, Examination 36185
MasterCard Visa
Total: 155731
Abstract [English] The present disclosure provides compositions and methods for delivering a gene of interest to a subject. Aspects of the application relate to nucleic acids encoding modified retroelement- derived polypeptides and gene delivery constructs that can direct integration of a nucleic acid sequence into a target nucleic acid (e.g., a genome of a subject). [French] La présente divulgation concerne des compositions et des procédés pour administrer un gène d'intérêt à un sujet. Des aspects de la divulgation concernent des acides nucléiques codant pour des polypeptides dérivés de rétroéléments modifiés et des constructions d'administration de gènes qui peuvent diriger l'intégration d'une séquence d'acides nucléiques dans un acide nucléique cible (par exemple, un génome d'un sujet).